Search

Your search keyword '"Riely, Gregory J."' showing total 1,489 results

Search Constraints

Start Over You searched for: Author "Riely, Gregory J." Remove constraint Author: "Riely, Gregory J."
1,489 results on '"Riely, Gregory J."'

Search Results

1. Automated real-world data integration improves cancer outcome prediction

3. Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors

4. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor[FIGURE DASH]Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

6. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

8. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

9. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis

10. Genomic mapping of metastatic organotropism in lung adenocarcinoma

12. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

13. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers

14. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer.

16. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

18. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

20. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

23. Mesothelioma: Pleural, Version 1.2024

24. Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

25. Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

26. Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

27. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

28. Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

29. Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

30. TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

31. FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

32. TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

33. FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

34. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

38. Supplementary Figures S1-9 from MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

41. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

42. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

44. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

46. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

49. Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors.

Catalog

Books, media, physical & digital resources